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Abstract
Background Cachexia is a formidable clinical challenge in pancreatic cancer. We assessed LY2495655 (antimyostatin anti-
body) plus standard-of-care chemotherapy in pancreatic cancer using cachexia status as a stratiﬁer.
Methods In this randomized, phase 2 trial, patients with stage II–IV pancreatic cancer were randomized to 300 mg
LY2495655, 100 mg LY2495655, or placebo, plus physician-choice chemotherapy from a prespeciﬁed list of standard-of-care
regimens for ﬁrst and later lines of care. Investigational treatment was continued during second-line treatment. The primary
endpoint was overall survival.
Results Overall, 125 patients were randomized. In August 2014, 300 mg LY2495655 was terminated due to imbalance in
death rates between the treatment arms; in January 2015, 100 mg LY2495655 treatment was terminated due to futility.
LY2495655 did not improve overall survival: the hazard ratio was 1.70 (90% conﬁdence interval, 1.1–2.7) for 300 mg vs.
placebo and 1.3 (0.82–2.1) for 100 mg vs. placebo (recommended doses). Progression-free survival results were consistent
with the overall survival results. A numerically higher hazard ratio was observed in patients with weight loss (WL) of ≥5%
(cachexia) than with <5% WL within 6 months before randomization. Subgroup analyses for patients stratiﬁed by WL in
the 6 months preceding enrollment suggested that functional responses to LY2495655 (either dose) may have been superior
in patients with <5% WL vs. patients with ≥5% WL. Among possibly drug-related adverse events, fatigue, diarrhoea, and
anorexia were more common in LY2495655-treated than in placebo-treated patients.
Conclusions In the intention-to-treat analysis, LY2495655 did not confer clinical beneﬁt in pancreatic cancer. Our data
highlight the importance of assessing survival when investigating therapeutic management of cachexia and support the use
of WL as a stratiﬁer (independent of performance status).
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Introduction
The overall prognosis for pancreatic cancer remains poor
with a 5-year survival rate of 7% (for all stages combined).1
Cachexia, a complex, multifactorial syndrome characterized
by loss of skeletal muscle that is not reversible with
nutritional support,2,3 is prominent in many malignancies
including pancreatic cancer4 and leads to decreased physical
function, reduced tolerance to anticancer therapy, and
decreased overall survival (OS).
Cachexia research has identiﬁed several promising drug
targets, including myostatin, a member of the transforming
growth factor-β superfamily.5 Animal studies have demon-
strated that myostatin is a highly conserved negative
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regulator of skeletal muscle mass.6–13 In mouse cancer
cachexia models, inhibition of the myostatin signalling path-
way is associated with improvements in body weight, muscle
volume, and physical performance.6,14
The myostatin-neutralizing mouse IgG1monoclonal anti-
body (mAb), LSN2478185, and its humanized derivative,
LY2495655, signiﬁcantly attenuated the loss of muscle mass
and improved strength in mouse tumour models without af-
fecting tumour growth.7 Importantly, co-administration of
these antibodies with gemcitabine did not reduce their
strength preservation effects. In a multicentre phase 1 study,
the safety and recommended doses of LY2495655 were
assessed in 29 patients with advanced cancer; all doses of
LY2495655 in the dose-escalation phase (2, 7, 21, 70, 210,
and 700 mg once every 2 weeks [Q2W]) and dose-expansion
phase (100 and 300 mg Q2W) appeared to be well-tolerated
with no signiﬁcant safety concerns.15 The recommended
doses of LY2495655 were 100 and 300 mg Q2W.
The goal of this clinical trial was to investigate the effects
of LY2495655 plus standard-of-care chemotherapy regimen
on OS, changes in muscle mass, and physical performance
in locally advanced, inoperable, or metastatic pancreatic
cancer. This was the ﬁrst large, randomized trial with an
emphasis on treating the cachexia syndrome in patients with
pancreatic cancer using an especially comprehensive meth-




This multicentre, randomized, double-blind, placebo-controlled,
phase 2 trial enrolled patients with locally advanced, inopera-
ble, or metastatic pancreatic cancer (NCT01505530). Patients
were randomized into three treatment arms: chemotherapy
plus 300 mg LY2495655 (hereafter 300 mg), chemotherapy plus
100 mg LY2495655 (hereafter 100 mg), or chemotherapy plus
placebo (hereafter placebo) (Supporting Information Appendix
S1). Investigators chose either a single-agent gemcitabine,
gemcitabine plus erlotinib, or FOLFIRINOX as a ﬁrst-line treat-
ment; therefore, chemotherapy was not assigned in the study
but rather selected by the treating physicians based on patient
age, performance, and co-morbidities. Randomization was
stratiﬁed by treatment regimen (gemcitabine vs. gemcitabine
plus erlotinib vs. FOLFIRINOX), disease stage (II/III vs. IV),
Eastern Cooperative Oncology Group (ECOG) performance
status (PS) (0/1 vs. 2), and percentage of weight loss (WL)
occurring within 6 months of enrollment (<5%vs. ≥5%). An
assessment committee reviewed unblinded adverse event
(AE) and serious AE data during an initial safety lead-in and
every 6 months thereafter. Protocols were approved by Ethical
Review Boards, and signed informed consent was obtained
prior to study procedures. Trials were compliant with the
Declaration of Helsinki and other applicable guidelines.
LY2495655 was administered intravenously (IV) over 30
(±5) min every 14 days. Cycle 1 was 8 weeks and included
four planned doses of study therapy (described in
Supporting Information Appendix S2). Subsequent cycles
were 4 weeks with two planned doses of treatment.
FOLFIRINOX was dosed as described in Supporting Informa-
tion Appendix S2. Patients continued treatment until dis-
ease progression, intolerable AEs, or patient/investigator
decision. If the patient experienced disease progression
on ﬁrst-line therapy or did not tolerate ﬁrst-line therapy,
the patient could receive post-ﬁrst-line chemotherapy of
mFOLFOX6, 5-ﬂuorocuracil, capecitabine, gemcitabine-based
regimen, or best supportive care while continuing on study
therapy or placebo.
Palpable tumour assessments were performed at the end
of every treatment cycle; radiologic assessments were
performed every 8 weeks. Muscle volume of the thigh and
L4-L5 region was measured as described.16 Functional assess-
ments were performed every 8 weeks (6 min walk, hand grip
strength, and timed up and go test) and at 4 weeks and every
8 weeks thereafter (stair climb) (Supporting Information
Appendix S2).
Eligibility criteria
Males and females aged ≥18 years (ECOG PS ≤2) with
histologically or cytologically diagnosed locally advanced
(stage II/III) or metastatic (stage IV) pancreatic adenocarci-
noma whose cancer was either not amenable to resection
with curative intent or who had progression after prior
surgery were eligible. Other inclusion criteria included
measurable/nonmeasurable disease (RECIST version 1.117),
an estimated life expectancy of ≥12 weeks, a requirement
to perform all performance measures at baseline, and having
received radiotherapy (where applicable) ≥4 weeks before
study enrollment. Key exclusion criteria included completion
of a prior study investigating a drug speciﬁcally targeting
myostatin, central nervous system malignancies, orthopaedic
or neurologic injury <6 months before randomization, prior
systemic chemotherapy for unresectable/metastatic disease,
endocrine pancreatic tumours or ampullary cancer,
underlying muscle disease, and use of muscle-building or
performance-enhancing medications. All patients provided
written informed consent before study procedures.
Outcome measures
The primary endpoint was OS. Secondary outcomes included
progression-free survival (PFS), tumour response rate,
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duration of response, body composition, thigh muscle
volume and recto-femoral area, and physical performance
outcomes (Supporting Information Appendix S2).
Statistical analysis
Enrollment of 120 patients provided 74% power with a type I
error rate of 0.20 to detect 20% OS improvement (hazard ra-
tio [HR] = 0.83) and 40% OS improvement (HR = 0.71) in low-
dose and high-dose arms, respectively, assuming a median OS
time of 6.5 months for the gemcitabine-based stratum and
11 months for the FOLFIRINOX stratum.18,19 This calculation
was performed using a Bayesian Augmented Control model.
Efﬁcacy analysis included the intent-to-treat population.
Statistical analyses were conducted using Statistical Analysis
Software® (SAS Institute Inc, Cary NC, USA). Time-to-event
outcomes were estimated using the Kaplan–Meier method,20
and 90% conﬁdence intervals (CIs) were estimated using the
Greenwood method.21 A Cox proportional hazard model22
was used to estimate HR values and two-sided 90% CI after
adjusting for the aforementioned stratiﬁcation factors as well
as age, gender, and investigational site. Tumour response
rates were compared between the treatment arms using a
continuity-corrected χ2 test, and the 90% CIs were
constructed using the normal approximation to the binomial
distribution.
Subgroup analyses of OS, PFS, and select functional and
muscle outcomes were performed by baseline WL (<5%
and ≥5%), ECOG PS (0–2), age, gender, and choice of ﬁrst-line
chemotherapy (gemcitabine alone vs. gemcitabine plus
erlotinib vs. FOLFIRINOX).
Treatment-emergent adverse events (TEAEs) were deﬁned
as AEs that occurred or whose severity worsened after the
ﬁrst administration of any study drug regardless of study drug
causality. The Medical Dictionary for Regulatory Activities ver-
sion 13.0 (or higher) Lower Level Term was used to identify
treatment emergence. TEAEs were graded using Common
Terminology Criteria for Adverse Events version 4.02. Planned
interim analyses were conducted to assess safety.
Results
Study population
Of 167 enrolled patients, 125 were randomized (41, 300 mg;
42, 100 mg; 41, placebo) to ﬁrst-line therapy (Figure 1). One
patient assigned to 100 mg was not treated. Thirty-six
patients (28.8%) received second-line therapy including two
Figure 1 Patient ﬂow diagram.
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patients who did not complete one cycle of ﬁrst-line therapy
(1 300 mg-treated patient; 1 placebo-treated patient). Five
patients received third-line therapy, and one received
fourth-line therapy.
Of patients completing ≥1 cycles of ﬁrst-line therapy,
36.6%, 23.3%, and 22.0% received second-line therapy in
the 300 mg, 100 mg, and placebo arms, respectively
(Table 1). No signiﬁcant differences in baseline characteristics
between treatment arms were observed, except for number
of patients with WL ≥5% within the 6 months preceding en-
rollment, which was numerically higher in the 100 mg arm
(Table 1). Baseline myostatin levels were similar across treat-
ment arms and in men vs. women (Supporting Information
Appendix S3).
Interim analyses
Safety interim analyses were planned after completion of
cycle 1 by 18 patients and every 6 months thereafter. Four
interim analyses were performed by an internal assessment
committee: December 2012 (safety), July 2013 (futility/
safety, approximately 3 months after enrollment of the 45th
patient), February 2014 (futility/safety, approximately
3 months after enrollment of the 80th patient), and August
2014 (safety). The assessment committee recommended con-
tinuation of the trial without modiﬁcation after each of the
ﬁrst three interim analyses. At the August 2014 interim
analysis (data lock: 31 July 2014), the committee noted an
imbalance in deaths among patients with long-term follow-up
Table 1 Patient baseline characteristics
Characteristic 300 mg (n = 41) 100 mg (n = 43) Placebo (n = 41)
Gender, n (%)
Women 16 (39) 13 (30) 15 (37)
Age, years
Mean (SD) 65.0 (1.3) 67.4 (10.7) 68.4 (9.1)
Median (range) 66.7 (44.8–82.0) 66.7 (47.3–85.6) 70.2 (46.6–84.5)
Race, n (%)
Asian 0 (0) 0 (0) 1 (2.4)
Black or African American 3 (7.3) 1 (2.3) 5 (12.2)
White 38 (92.7) 42 (97.7) 35 (85.4)
Weight, kg
Mean (SD) 72.6 (16.7) 71.5 (19.5) 71.2 (14.1)
Median (range) 70.8 (41.6–112.7) 66.1 (35.3–155.2) 72.3 (43.9–115.0)
Lean mass, kg
Mean 43.7 44.3 42.9
Median (range) 41.6 (21.7–72.1) 45.8 (20.3–60.8) 40.7 (24.7–68.9)
Fat mass, kg
Mean 22.1 18.2 21.2
Median (range) 20.0 (1.6–44.7) 16.9 (3.0–37.5) 19.7 (6.7–43.0)
First-line therapy, n (%)
Gemcitabine 15 (36.6) 15 (34.9) 16 (39.0)
Gemcitabine + erlotinib 15 (36.6) 15 (34.9) 15 (36.6)
FOLFIRINOX 11 (26.8) 12 (27.9) 10 (24.4)
Second-line therapy, n (%) 15 (36.6) 10 (23.3) 9 (22.0)
Best supportive care 2 (4.9) 2 (4.7) 4 (9.8)
Capecitabine 6 (14.6) 1 (2.3) 2 (4.9)
Gemcitabine 0 1 (2.3) 0
Gemcitasbine + erlotinib 2 (4.9) 3 (7.0) 0
mFOLFOX6 6 (14.6) 3 (7.0) 3 (7.3)
5-ﬂuorouracil 0 0 1 (2.4)
Disease stage at diagnosis, n (%)
II 6 (14.6) 1 (2.3) 5 (12.2)
III 7 (17.1) 8 (18.6) 7 (17.1)
IV 28 (68.3) 34 (79.1) 29 (80.7)
ECOG PS, n (%)
0 17 (41.5) 16 (37.2) 15 (36.6)
1 23 (56.1) 26 (60.5) 25 (61.0)
2 1 (2.4) 1 (2.3) 1 (2.4)
Weight loss within 6 months before enrollment, n (%)
<5% decrease 19 (46.3) 13 (30.2) 18 (43.9)
≥5% decrease 22 (53.7) 30 (69.8) 23 (56.1)
Patients completing ≥1 cycles of ﬁrst-line
therapy and receiving second-line therapy, n (%)
15 (36.6) 10 (23.2) 9 (22.0)
ECOG, Eastern Cooperative Oncology Group; mFOLFOX6, folinic acid (leucovorin)-ﬂuorouracil-oxaliplatin; PS, performance status; SD,
standard deviation.
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who received 300 mg (31 deaths), 100 mg (19 deaths), and pla-
cebo (17 deaths). All deaths in this category were attributable
to study disease and were not explained by any observed dif-
ference in AEs or other factors that were examined. Deaths
on study drug and within 30 days of discontinuation were
balanced across treatment arms. Consequently, LY2495655
300mg treatment was discontinued. After the data cut-off date
(January 2015), LY2495655 was discontinued in all those
receiving it during the extension phase because the primary
objective was not met, and no improvement in assessed phys-
ical performance measures was observed.
Efﬁcacy
There were 32 (78.0%), 30 (69.8%), and 25 (61.0%) deaths
with 300 mg, 100 mg, and placebo, respectively (Table 2).
Most deaths were disease-related, and only a few were re-
lated to AEs. No signiﬁcant OS beneﬁt was observed with
LY2495655 (HR = 1.7 [90% CI, 1.1–2.7] for 300 mg vs. placebo;
HR = 1.3 [90% CI, 0.82–2.1] for 100 mg vs. placebo) (Fig-
ure 2A). Median OS was 8.0 months (90% CI, 6.0–10.0) for
300 mg, 9.8 months (90% CI, 5.9–13.5) for 100 mg, and
10.5 months (90% CI, 8.4–14.5) for placebo. Similarly, no sig-
niﬁcant PFS beneﬁt was observed with LY2495655 (HR = 2.5
[90% CI, 1.6–4.0] for 300 mg vs. placebo; HR = 1.5 [90% CI,
1.0–2.3] for 100 mg vs. placebo) (Figure 2B). Median PFS
was 4.9 months (90% CI, 3.3–6.0) for 300 mg, 6.9 months
(90% CI, 5.4–7.9) for 100 mg, and 8.2 months (90% CI, 5.0–
9.4) for placebo. Results of the preplanned Bayesian analysis
are not presented due to the apparent lack of efﬁcacy.
Preplanned subgroup analyses demonstrated that the ef-
fect of LY495655 on OS may differ based on WL history. A nu-
merically worse HR was observed for patients with ≥5% WL
within 6 months before randomization (HR = 2.4 [90% CI,
0.49–2.0] for 300 mg vs. placebo; HR = 1.4 [90% CI, 0.81–
2.5] for 100 mg vs. placebo) than for those with <5% WL
within 6 months before randomization (HR = 0.99 [90% CI,
0.49–2.0] for 300 mg vs. placebo; HR = 0.87 [90% CI, 0.40–
1.9] for 100 mg vs. placebo) (Table 3). No other interactions
between prognostic factors and OS were observed (Table 3).
Baseline characteristics were similar between groups of pa-
tients with <5% or ≥5% WL in the 6 months before enroll-
ment (Supporting Information Appendix S4). In patients
with ≥5% previous WL, baseline characteristics were
similar across treatment groups (Supporting Information
Appendix S5).
Investigator-reported objective tumour response rates
were 22.0%, 25.6%, and 26.8% for 300 mg, 100 mg, and pla-
cebo, respectively. The median response duration was 5.9
(90% CI, 3.9–8.6) months for 300 mg, 8.0 (90% CI, 3.1–9.6)
for 100 mg, and 9.2 (90% CI, 9.0–10.5) for placebo.
Changes in mass and functional evaluations from baseline
to approximately 8 weeks are shown in Table 4. There were
no signiﬁcant improvements in muscle volume (as measured
by both dual-energy X-ray absorptiometry and computed to-
mography scans) or functional tests between LY249655-
treated (100 or 300 mg) and placebo-treated patients. Analy-
sis of later visits was limited because of sample size but ap-
peared to be consistent with the ﬁndings at the 8-week
assessment. The only signiﬁcant difference observed be-
tween LY2495655 and placebo was with respect to improve-
ment in 6 min walk from baseline to approximately 8 weeks.
This difference was without adjusting for multiplicity and was
only for the 300 mg dose (least squares means differ-
ence = 52.5 m; 90% CI, 3.9–101.1) but not for the 100 mg
dose (least squares means difference = 32.9 m; 90% CI,
82.3–16.5).
Mass and functional evaluations by WL subgroups demon-
strated that response to LY2495655 (vs. placebo) was better
in patients with <5% WL (precachexia) than in those with
≥5% WL (cachexia). The evaluations in which these differ-
ences (which were not necessarily statistically signiﬁcant)
were observed included body mass measures (thigh muscle
volume, lean mass, fat mass) and functional measurements
(hand grip, 6 min walk distance) (Table 5).
The pharmacokinetics of LY2495655 demonstrated a pat-
tern of drug concentration–dependent nonlinearity. Popula-
tion pharmacokinetics analysis revealed a half life for
LY2495655 of approximately 12 to 23 days. Gemcitabine
clearance was not affected by LY2495655 doses or by erloti-
nib doses. Erlotinib drug exposure appeared not to be af-
fected by LY2495655 treatment. Based on the results from
the target-engagement model, almost complete target en-
gagement (>95%) was achieved for both the 100 and
300 mg LY2495655 IV arms.
Safety
No dose-exposure imbalances were observed between study
arms (Supporting Information Appendix S6). Modest differ-
ences were observed between the study arms with respect
to TEAEs and serious adverse events (Supporting Information
Appendix S7); however, these differences did not demon-
strate a clear pattern of toxicity relationship between treat-
ment arms. Overall, 18 deaths (14.5%) were reported for
patients on therapy, 27 deaths (21.8%) were reported for







Death, n (%) 32 (78) 30 (70) 25 (61)
Due to study disease 29 (71) 25 (58) 23 (56)
Due to adverse event 3 (7) 5 (12) 2 (5)
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patients within 30 days of discontinuation, and 42 deaths
(33.9%) were reported beyond 30 days of discontinuation.
The majority of deaths were due to the underlying study dis-
ease. AE-related deaths occurred in 7 (2 300 mg; 3 100 mg; 2
placebo), 3 (1 300 mg; 2 100 mg), and 0 patients on therapy,
within 30 days of discontinuation, and beyond 30 days of dis-
continuation, respectively, but none were study drug-related
as determined by the investigator.
Two patients discontinued LY2495655 treatment due to
AEs: 1 patient (300 mg arm) discontinued due to Grade 3
blood bilirubin increase during cycle 1 (unrelated to treat-
ment), and a second patient (100 mg arm) discontinued
due to Grade 2 hypersensitivity during cycle 1 (possibly
treatment-related).
The most common TEAEs regardless of causality were fa-
tigue, diarrhoea, anorexia, nausea, decreased platelet count,
anaemia, fever, vomiting, edema of the limbs, decreased neu-
trophil count, abdominal pain, constipation, dyspnea, and
oral mucositis. Notable differences between the treatment
arms in TEAE incidence were in the rates of decreased
Figure 2 Overall survival (A) and progression-free survival (B) by study arm.
A
B
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neutrophil count (39.0%, 23.8%, and 43.9% in the 300 mg,
100 mg, and placebo arms, respectively), oral mucositis
(36.6%, 21.4%, and 22.0%, respectively), and other
infections/infestations (2.4%, 7.1%, and 24.4%, respectively).
Among possibly study drug–related TEAEs, fatigue was
more common in placebo-treated than LY2495655-treated
patients (26.8%, 38.1%, and 51.2% in the 300 mg, 100 mg,
and placebo arms, respectively), as were diarrhoea (26.8%,
23.8%, and 39.0%, respectively) and anorexia (17.1%,
16.7%, and 31.7%, respectively).
Discussion
In patients with stage II–IV unresectable pancreatic cancer
receiving chemotherapy, LY2495655 administration did not
improve OS compared with placebo. Indeed, compared with
placebo, a trend toward poorer OS was observed with
LY2495655. The median OS reported here (8.0, 9.8, and
10.5 months for the 300 mg, 100 mg, and placebo arms,
respectively) seems similar to modern chemotherapy treat-
ments for the placebo arm23–27; Chauffert et al. have reported
OS of up to 13 months with the induction gemcitabine group
(GEM: 1000 mg/m2 weekly for 7 weeks) vs. 8.6 months in the
CHRT group (60 Gy, 2 Gy/fraction; concomitant 5-ﬂuorouracil
infusion, 300 mg/m2/day, days 1–5 for 6 weeks; cisplatin,
20mg/m2/day, days 1–5 during weeks 1 and 5) in patients with
advanced pancreatic cancer.28 Although sample size may have
limited the ability to demonstrate an interaction, with the
exception of WL history, no other interactions between
prognostic factors and OS were apparent.
The study’s OS ﬁndings are consistent with results for
the secondary endpoints, including PFS, tumour response
rate, and duration of response. The median PFS observed
here (4.9, 6.9, and 8.2 months for the 300 mg, 100 mg,
and placebo arms, respectively) are also somewhat longer
than historical values reported in gemcitabine-treated
Table 4 Change from baseline to 8 weeks in mass and functional
evaluation
Evaluation
300 mg – Placebo
Difference (90% CI)
100 mg – Placebo
Difference (90% CI)










































ADL, activities of daily living; CI, conﬁdence interval; CT, computed
tomography; DXA, dual-energy X-ray absorptiometry.







Gemcitabine 46 1.6 (0.80–3.3) 0.93 (0.45–1.9)
Gemcitabine + erlotinib 45 1.2 (0.59–2.3) 1.4 (0.70–2.6)
FOLFIRINOX 33 3.2 (1.0–9.9) 1.7 (0.52–5.8)
ECOG PS
0 43 1.3 (0.63–2.9) 0.95 (0.41–2.2)
1 or 2 82 1.6 (0.91–2.7) 1.3 (0.78–2.3)
Disease stage
II/III 34 1.5 (0.57–3.7) 1.1 (0.41–3.1)
IV 91 1.7 (1.0–2.8) 1.4 (0.80–2.3)
Weight loss in last 6 months
<5% decrease 50 0.99 (0.49–2.0) 0.87 (0.40–1.9)
≥5% decrease 75 2.4 (1.3–4.2) 1.43 (0.81–2.5)
CI, conﬁdence interval; ECOG, Eastern Cooperative Oncology
Group;HR, hazard ratio;OS, overall survival; PS, performance status.
Table 5 Change from baseline to 8 weeks in mass and functional evaluation by previous weight loss
Evaluation
300 mg – Placebo 100 mg – Placebo
<5% decrease ≥5% decrease <5% decrease ≥5% decrease
Thigh muscle, mL 172 100 114 27
Muscle area (CT), mm2 395 233 35 189.5
Fat area (CT), mm2 433 1414 553 1410
Lean mass (DXA), g 88 1288 501 547
Fat mass (DXA), g 1202 502 1357 342
Hand grip, kg 3.7 1.0 4.2 1.5
Stair climbing power,a mL Joule/sec 23.4 14.8 5.1 7
6 min walk distance, m 82 24 16 57
Timed up and go, sec 0.2 3.3 0.1 0.25
Pancreatic ADL, points 2.2 3.2 4.4 0.34
Bolded numbers indicate a better score in the <5% decrease group compared with ≥5% decrease group. ADL, activities of daily living;
CT, computed tomography; DXA, dual-energy X-ray absorptiometry.
aEvaluated at 12 weeks.
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patients.18,19 The possibly longer OS and PFS observed here
may be related to the use of FOLFIRINOX as an alternative
regimen delivering a median OS of 11 months.26 It is also
possible that this is related to between-arm imbalances in
the enrollment of early-stage patients. Notably, we
stratiﬁed patients by WL, which is unique to this trial.
The observed association of WL category with outcome
was independent of ECOG status and could potentially
serve as an important variable in future pancreatic cancer
research. Consistent with the observed lack of improve-
ments in survival (OS and PFS) to study drug, we did not
ﬁnd clinically and statistically signiﬁcant improvements with
LY2495655 in the assessed physical performance measures
(except for the 6 min walk with the 300 mg dose). How-
ever, it is still possible that subgroups of patients beneﬁted
from LY2495655. When AEs were considered, there were
no obvious factors that could have inﬂuenced the ﬁndings.
In the 300 mg, 100 mg, and placebo arms, respectively,
rates of infections/infestations were 2.4%, 7.1%, and
21.4%, suggesting the possibility that LY2495655 may help
prevent infection in these patients.
These ﬁndings are in contrast to those from a random-
ized trial involving elderly patients who had a fracture from
a fall before enrollment, wherein LY2495655 treatment in-
creased lean body mass and possibly improved functional
measures of muscle power.29 Another trial demonstrated
that inhibition of myostatin with AMG 745 increased lean
body mass and decreased fat mass after 29 days in men
with prostate cancer who were undergoing antiandrogen
therapy.30 In our study, we observed superior responses
to LY2495655 in patients with <5% previous WL compared
with patients with ≥5% previous WL. This ﬁnding was inde-
pendent of ECOG PS. These data suggest that patients who
are precachexic (deﬁned by WL) at baseline fare better in
terms of performance measures than cachexic patients. It
is possible that those with more profound WL were gener-
ally too sick to beneﬁt from LY2495655; additionally,
LY2495655 may be more effective at preventing muscle
wasting than reversing cachexia.
Myostatin can have conﬂicting effects on cachexia. In
preclinical models, myostatin-null mice that were injected
with cancer cells were more sensitive to tumour-induced
cachexia than wild-type mice.12 Although myostatin over-
expression can cause cachexia in mice,31 it is not the sole
mediator.12 Signalling via the activin type II receptor ap-
pears to play a key role in development and progression
of cachexia,32 but myostatin is only one of multiple li-
gands for this receptor.33 The abnormal metabolism that
is associated with cachexia is caused by a complex inter-
play of host-derived and tumour-derived factors.5,34–36
Therefore, it is possible that inhibition of myostatin with
LY2495655 caused a compensatory change in other fac-
tor(s) that negatively impacted this study population. For
example, tumour biology may have forced a shift in search
of amino acids that were no longer accessible from the
muscle breakdown pathway. This study’s observations sug-
gest that multi-modal interventions are likely needed to
maximize care, and those interventions may be different
or of different intensity depending on the existing level
of WL. In this context, development of other cachexia-
modulating targets and combinatorial strategies are impor-
tant areas for future research.
Additional analyses, including that of subgroups and ex-
ploratory biomarkers, are ongoing. These analyses may help
determine optimal myostatin-based treatment regimens ac-
cording to clinical and molecular characteristics of patients.
This is the ﬁrst large, randomized trial to address the ca-
chexia syndrome. Even though our results were negative,
extensive effort from the patients and investigators in the
secondary functionality endpoints was performed, thus
helping to further develop functional readouts in pancreatic
cancer.
In conclusion, although the study failed to meet its primary
objectives, the results highlight the importance of including
survival endpoints in studies addressing therapeutic manage-
ment of cachexia. The data also support the use of WL in pan-
creatic cancer trials as a clinically important stratiﬁcation
factor that is independent of PS.
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